<DOC>
	<DOCNO>NCT00003079</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell . PURPOSE : Phase I trial study effectiveness bryostatin 1 high dose cytarabine treat patient refractory relapse acute myelocytic acute lymphocytic leukemia , chronic myelogenous leukemia refractory relapse lymphoblastic lymphoma .</brief_summary>
	<brief_title>Bryostatin 1 High Dose Cytarabine Treating Patients With Refractory Relapsed Leukemia Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I . Define maximum tolerate dose ( MTD ) bryostatin 1 administer high dose cytarabine patient refractory relapse acute myelocytic leukemia acute lymphocytic leukemia , chronic myelogenous leukemia , refractory relapse lymphoblastic lymphoma . II . Describe toxic effect bryostatin 1 high dose cytarabine patient . III . Describe time course bryostatin 1 induced modulation leukemic blast total protein kinase C ( PKC ) activity . IV . Describe bryostatin 1 pharmacokinetics . V. Correlate bryostatin 1 induced modulation leukemic cell PKC activity leukemic cell maturation high dose cytarabine mediate apoptosis . OUTLINE : This dose escalation study . Patients receive bryostatin 1 continuous infusion 24 hour day 1 . One hour completion bryostatin 1 , patient receive high dose cytarabine IV 3 hour every 12 hour day 2-4 . Patients receive cytarabine 3 hour every 12 hour day 9-11 , follow 1 hour later bryostatin 1 continuous infusion 24 hour begin day 11 . Patients achieve complete remission may receive 4 course consolidation chemotherapy . Consolidation chemotherapy induction chemotherapy except patient receive 2 dos cytarabine day 1 completion bryostatin 2 dos cytarabine prior day 11 dose bryostatin . Patients achieve partial remission may receive second course induction chemotherapy . In absence dose limit toxicity first 3 patient treat , subsequent cohort 6 patient receive escalate dos bryostatin 1 schedule . If dose limit toxicity occur 2 6 patient give dose level , dose escalation cease current dose define maximum tolerated dose . Patients follow every 6 month death . PROJECTED ACCRUAL : A total 12-50 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Bryostatin 1</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm primary refractory relapse acute myelocytic leukemia ( AML ) acute lymphocytic leukemia ( ALL ) , chronic myelogenous leukemia ( CML ) blast crisis , refractory relapse lymphoblastic lymphoma Priority give patient previously treat conventional high dose cytarabine regimen without bryostatin 1 Eligible previously fail conventional high dose cytarabine regimen underwent subsequent high dose therapy bone marrow/stem cell transplantation curative intent PATIENT CHARACTERISTICS : Age : 18 ( must 60 receive high dose cytarabine ) Performance status : Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin great 2.0 mg/dL ( bilirubin great 3.0 mg/dL conjugate bilirubin great 0.5 mg/dL Gilbert 's disease predominantly unconjugated hyperbilirubinemia present ) AST great 2.5 time upper limit normal ( ULN ) Alkaline phosphatase great 2.5 time ULN Renal : Creatinine clearance least 40 mL/min ( least 60 mL/min receive high dose cytarabine ) Pulmonary : No clinically significant pulmonary disease Other : Not pregnant No patient poor medical risk nonmalignant systemic disease No serious , active , uncontrolled infection No prior concurrent medical status would make assess cortical cerebellar neurologic toxicity difficult PRIOR CONCURRENT THERAPY : Recovery major toxic effect prior therapy require Biologic therapy : See Disease Characteristics Chemotherapy : See Disease Characteristics At least 24 hour since prior chemotherapy hydroxyurea At least 3 week since prior systemic chemotherapy No prior clinically significant cerebellar toxicity due cytarabine Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
</DOC>